UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses

Value in health, 2021-11, Vol.24 (11), p.1643-1650

2021

Volltextzugriff (PDF)

Special Issue PRO-Analysis of Clinically Meaningful Change on Patient-Reported Outcomes: Renewed Insights About Covariate Adjustment

Journal of biopharmaceutical statistics, 2023-08, p.1-14

2023

Volltextzugriff (PDF)

Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study

BMC medical research methodology, 2023-01, Vol.23 (1), p.18-18, Article 18

2023

Volltextzugriff (PDF)

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

BMC musculoskeletal disorders, 2022-02, Vol.23 (1), p.106-106, Article 106

2022

Volltextzugriff (PDF)

Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions

Journal of biopharmaceutical statistics, 2023-11, p.1-13

2023

Volltextzugriff (PDF)

Climate and Tick Seasonality Are Predictors of Borrelia burgdorferi Genotype Distribution

Applied and Environmental Microbiology, 2009-04, Vol.75 (8), p.2476-2483

2009

Volltextzugriff (PDF)

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis?

Expert opinion on pharmacotherapy, 2012-05, Vol.13 (7), p.1077-1078

2012

Volltextzugriff (PDF)

Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4515-4515

2023

Volltextzugriff (PDF)

Effects of radium-223 dichloride (Ra-223) on risk for hospitalization and health care resource use in the phase 3 ALSYMPCA trial

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.21-21

2014

Volltextzugriff (PDF)

Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI‐18) in patients with advanced urothelial cancer

Cancer, 2024-01, Vol.130 (1), p.31-40

2024

Volltextzugriff (PDF)

Reliability, validity, and clinically important differences (CIDs) on the NCCN/FACT Bladder Symptom Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.408-408

2021

Volltextzugriff (PDF)

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma

European urology, 2023-04, Vol.83 (4), p.320-328

2023

Volltextzugriff (PDF)

Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4516-4516

2023

Volltextzugriff (PDF)

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.508-508

2023

Volltextzugriff (PDF)

PD38-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup

Journal of clinical oncology, 2015-03, Vol.33 (7_suppl), p.254-254

2015

Volltextzugriff (PDF)

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

European journal of cancer (1990), 2017-01, Vol.71, p.1-6

2017

Volltextzugriff (PDF)

Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States

The American journal of tropical medicine and hygiene, 2012-02, Vol.86 (2), p.320-327

2012

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.116-116

2024

Volltextzugriff (PDF)

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.109-109

2024

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5013-5013

2023

Volltextzugriff (PDF)

An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15601-e15601

2013

Volltextzugriff (PDF)

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

The lancet oncology, 2023-06, Vol.24 (6), p.e270-e283

2023

Volltextzugriff (PDF)

Field and climate-based model for predicting the density of host-seeking nymphal Ixodes scapularis, an important vector of tick-borne disease agents in the eastern United States

Global ecology and biogeography, 2010-07, Vol.19 (4), p.504-514

2010

Volltextzugriff (PDF)

Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5069-5069

2014

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(30)
Dissertationen
(1)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(10)
Clinical Trials
(5)
Biological And Medical Sciences
(4)
Oncology
(4)
Patients
(4)
Quality Of Life
(4)
Analysis
(3)
Animals
(3)
Bladder Cancer
(3)
Borrelia Burgdorferi
(3)
Cancer
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)
Health Care Sciences & Services
(3)
Life Sciences
(3)
Male
(3)
Pharmacology & Pharmacy
(3)
Physical Sciences
(3)
Animal And Plant Ecology
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses

Special Issue PRO-Analysis of Clinically Meaningful Change on Patient-Reported Outcomes: Renewed Insights About Covariate Adjustment

Comparing g-computation, propensity score-based weighting, and targeted maximum likelihood estimation for analyzing externally controlled trials with both measured and unmeasured confounders: a simulation study

Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

Meaningful within-patient change for clinical outcome assessments: model-based approach versus cumulative distribution functions

Climate and Tick Seasonality Are Predictors of Borrelia burgdorferi Genotype Distribution

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis?

Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis

Effects of radium-223 dichloride (Ra-223) on risk for hospitalization and health care resource use in the phase 3 ALSYMPCA trial

Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI‐18) in patients with advanced urothelial cancer

Reliability, validity, and clinically important differences (CIDs) on the NCCN/FACT Bladder Symptom Index (NFBISI-18) among individuals with locally advanced or metastatic urothelial cancer (UC)

Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma

Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy

PD38-02 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: LONG-TERM OUTCOMES FROM JAVELIN BLADDER 100 IN SUBGROUPS DEFINED BY FIRST-LINE CHEMOTHERAPY REGIMEN AND ANALYSIS OF OVERALL SURVIVAL FROM START OF FIRST-LINE CHEMOTHERAPY

Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Human Risk of Infection with Borrelia burgdorferi, the Lyme Disease Agent, in Eastern United States

Patient-reported outcomes (PROs) with talazoparib (TALA) plus enzalutamide (ENZA) vs. placebo (PBO) plus ENZA in men with metastatic castration-resistant prostate cancer (mCRPC): Subgroup analysis of patients with novel hormonal therapy (NHT) pretreatment in the TALAPRO-2 study

Patient reported outcomes (PROs) among patients with metastatic castration-resistant prostate cancer (mCRPC) by homologous recombination repair mutations (HRRm) gene clusters: Findings from the phase 3 TALAPRO-2 study cohort 2

Patient-reported outcomes (PROs) among men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 3 study (TALAPRO-2)

An economic analysis of axitinib and sorafenib for second-line treatment of cytokine-refractory patients with advanced renal cell carcinoma in the United States (US)

Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures

Field and climate-based model for predicting the density of host-seeking nymphal Ixodes scapularis, an important vector of tick-borne disease agents in the eastern United States

Patient-reported quality of life (QOL) analysis of radium-223 dichloride (Ra-223) evaluating pain relief from the phase 3 ALSYMPCA study

Suchergebnisse filtern